The treatment success rate of MDR-TB is 48%,which is lower than that of drug susceptible TB (85%) and the economic burden for MDR-TB at the individual and societal level is high owing to expensive second-line anti-TB drugs, repeated hospitalizations, the long-term treatment period, and productivity losses. 1,2

Bedaquiline is a new anti-TB agent in the diarylquinoline group developed primarily to treat MDR-TB and has received marketing approval in Korea following approval in the USA and Europe based on efficacy and safety data from pivotal phase II trials. 3  MDR-TB affects individual health-related quality of life and social productivity significantly and Korea has the highest prevalence of tuberculosis and mortality among OECD (Organization for Economic Cooperation and Development) member countries 1 . Therefore, a cost-effectiveness evaluation of bedaquiline under the Korea settings will enable health care providers to select the optimal therapeutic strategy for managing MDR-TB in South Korea and in other countries with incidences of MDR-TB or XDR-TB are similar to those of Korea.
To compare the cost-effectiveness of bedaquiline plus SR to that of SR alone for the treatment of MDR-TB or XDR-TB patients in South Korea. 

The transition probabilities related to sputum culture conversions were assumed based on only one data source, the C208 phase II clinical trial. Additional confirmative analyses should be performed when further study results are available in the future.
It is highly likely that bedaquiline will help to prevent transmission of MDR-TB and may have even broader economic benefits both to patients and society via decreased transmission but this was not addressed in the model.
The results of this study indicate that bedaquiline, as part of combination therapy is a cost effective option for the treatment of MDR (including XDR-TB patients) compared to the standard treatment alone under the Korean settings.
Objectives: Bedaquiline is a new drug used for the treatment of multidrug-resistant tuberculosis (MDR-TB). This study aimed to evaluate the cost-effectiveness of adding bedaquiline to a standard regimen (SR) for treating patients with MDR-TB, including extensively drug-resistant tuberculosis (XDR-TB) in South Korea.
Methods:
A cohort-based decision analytic model developed in a previously published study from the UK was used with the following parameters: a 20-year time horizon and a 5% discount rate for cost and effectiveness to evaluate the incremental cost-effectiveness ratios (ICER) of bedaquiline plus the SR and SR alone. The key parameters regarding the clinical data were available via the published phase 2 trial of bedaquiline results. Additional parameters for recurrence, cured status, lost to follow-up, surgery, death, cost, and health utility were based on Korean data if available, otherwise the international literature data were applied. Univariate and probabilistic sensitivity analyses were conducted.
Results: A patient on bedaquiline plus the SR gained 1.20 quality adjusted life years (QALYs) at 13,961,659 Korean won (KRW) (1,100 KRW = 1 USD) additional cost compared to a patient administered the SR alone with an incremental cost-utility ratio (ICUR) of 11,638,656 KRW/QALY.
Bedaquiline plus the SR had an 80% probability of being cost-effective at a willingness-to-pay threshold of 26,000,000 KRW when compared to the SR alone.
Conclusions:
The results of this study indicate that bedaquiline, as part of combination therapy is a cost-effective option for the treatment of MDR (including XDR-TB patients) in Korea compared to the standard treatment alone. 
RESULTS

Transition probabilities : efficacy related probabilities were based mainly on the pivotal study on bedaquiline (clinical study C208) and others were obtained from literatures. 
